Hepatology 2000, 32:1078–1088.PubMedCrossRef 3. Yuen AZD1390 in vivo MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL: Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine

therapy. Hepatology 2001, 34:785–791.PubMedCrossRef 4. Shamliyan TA, Johnson JR, MacDonald R, Shaukat A, Yuan JM, Kane RL, Wilt TJ: Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. J Gen Intern Med 2011, 26:326–339.PubMedCrossRef 5. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999, 341:1256–1263.PubMedCrossRef 6. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L: Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003, 36:687–696.PubMedCrossRef Cilengitide in vitro 7. Zoulim F, Locarnini S: Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology

2009, 137:1593–1608. e1591–1592PubMedCrossRef 8. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27:1670–1677.PubMedCrossRef Dapagliflozin 9. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ: Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with

lamivudine. Hepatology 1996, 24:711–713.PubMedCrossRef 10. Allen MI, Gauthier J, DesLauriers M, Bourne EJ, Carrick KM, Baldanti F, Ross LL, Lutz MW, Condreay LD: Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999, 37:3338–3347.PubMed 11. Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Koida I, Arase Y, Saitoh S, et al.: Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998, 27:1711–1716.PubMedCrossRef 12. Jardi R, Buti M, Rodriguez-Frias F, Cotrina M, Costa X, Pascual C, Smoothened Agonist Esteban R, Guardia J: Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J Virol Methods 1999, 83:181–187.PubMedCrossRef 13. Cane PA, Cook P, Ratcliffe D, Mutimer D, Pillay D: Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus. Antimicrob Agents Chemother 1999, 43:1600–1608.PubMed 14.